• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Carlyle to buy Baxter's kidney-care spinoff Vantive for $3.8 billion

cafead

Administrator
Staff member
  • cafead   Aug 13, 2024 at 11:42: AM
via Buyout firm Carlyle Group (CG.O) struck a deal to acquire Baxter’s kidney-care unit Vantive for $3.8 billion, the companies said on Tuesday.


The proceeds from the deal, which is expected to close by early 2025, will help medical-device maker Baxter reduce its debt pile. Baxter, which paid down about $2.8 billion of debt last year after divesting its biopharma unit, had long-term debt of $13.8 billion at the end of 2023.

article source